Volume 5.40 | Oct 24

Prostate Cell News 5.40 October 24, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Stromal TGF-β Signaling Induces AR Activation in Prostate Cancer
Investigators show that stromal TGF-β signaling induces comprehensive morphology changes of prostate cancer LNCaP cells. Furthermore, it induces AR activation in LNCaP cells in the absence of significant levels of androgen, as evidenced by induction of several AR target genes including PSA, TMPRSS2, and KLK4. [Oncotarget] Full Article
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

Bcl-2 Family Inhibition Sensitizes Human Prostate Cancer Cells to Docetaxel and Promotes Unexpected Apoptosis under Caspase-9 Inhibition
Researchers investigated the effect of combining docetaxel (DTX) with Bcl-2 family inhibitors using human prostate cancer cell lines (PC3, LNCaP, and DU145 cells). PC3 cells were less sensitive to DTX than were the other two cell lines. [Oncotarget] Full Article

SPARC Mediates Metastatic Cooperation between CSC and Non-CSC Prostate Cancer Cell Subpopulations
Comparative secretome analysis yielded 213 proteins differentially secreted between cancer stem cell (CSC)-enriched subpopulation (M) and non-CSC subpopulation (S) cells. Of these, the protein most abundantly secreted in S relative to M cells was SPARC. [Mol Cancer] Full Article

Polycomb Protein EZH2 Suppresses Apoptosis by Silencing the Proapoptotic miR-31
Scientists show that enhancer of zeste homolog 2 (EZH2) suppresses prostate cancer apoptosis by coordinating the epigenetic silencing of two proapoptotic microRNAs (miRNA), miR-205 and miR-31.
[Cell Death Dis]
Full Article

Antiandrogenic Mechanisms of Pesticides in Human LNCaP Prostate and H295R Adrenocortical Carcinoma Cells
Several pesticides suspected or known to have endocrine disrupting effects were screened for pro- or antiandrogenic proprieties by determining their effects on proliferation, prostatic specific antigen secretion and androgen receptor (AR) expression and AR phosphorylation in androgen-dependent LNCaP human prostate cancer cells. [Toxicol Sci] Abstract

Integrative Analysis of FOXP1 Function Reveals a Tumor Suppressive Effect in Prostate Cancer
Scientists found that forkhead box protein (FOXP) 1 acts as a tumor suppressor in prostate cancer through inhibiting cell proliferation and migration. They generated an extensive global map of FOXP1 binding sites and found that FOXP1 is directly involved in androgen receptor-mediated transcription. [Mol Endocrinol]
Abstract | Full Article

Reduced Expression of GDF-15 Is Associated with Atrophic Inflammatory Lesions of the Prostate
To examine the relationship between growth differentiation factor-15 (GDF-15) and prostatic inflammation, GDF-15 expression was measured by immunohistochemical staining in human prostatectomy specimens containing inflammation. To provide insight into a potential suppressive role for GDF-15 in inflammation, activation of inflammatory mediator nuclear factor of kappa B was measured in PC3 cells. [Prostate]
Abstract | Press Release


Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
Investigators determined the clinical utility of abiraterone and its impact on circulating androgens following ketoconazole. Abiraterone demonstrates modest clinical efficacy in metastatic castration-resistant prostate cancer patients previously treated with ketoconazole. [Clin Cancer Res] Abstract

Statin Use after Radical Prostatectomy Reduces Biochemical Recurrence in Men with Prostate Cancer
In 2,137 consecutive radical prostatectomy patients between 1998 and 2011 at Asan Medical Center, investigators assessed the presence and impact of statin use according to types, dose equivalents, and postoperative duration of usage. [Prostate] Abstract

Permanent Interstitial Low-Dose-Rate Brachytherapy for Patients with Low Risk Prostate Cancer
Scientists evaluated the influence of relevant patient- and treatment-related factors. The study population comprised 312 consecutive patients treated with permanent seed implantation. All patients were evaluable for analysis of overall survival and disease-specific survival, and 230 for biochemical relapse-free survival. [Strahlenther Onkol] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Revisiting STAT3 Signaling in Cancer: New and Unexpected Biological Functions
Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT) signaling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche. Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.
[Nat Rev Cancer]

MTA Family of Proteins in Prostate Cancer: Biology, Significance, and Therapeutic Opportunities
The authors summarize the current understanding of the role of MTA family members, particularly MTA1, with a special emphasis on prostate cancer. Recent discoveries have highlighted a critical role for MTA1 in inflammation-triggered prostate tumorigenesis, epithelial-to-mesenchymal transition, prostate cancer survival pathways, and site metastasis. [Cancer Metastasis Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Phase II Data for Progenics’ 1404 Imaging Agent Presented
Progenics Pharmaceuticals, Inc. announced that data from a Phase II trial of its PSMA imaging agent candidate, 1404, have been presented. [Press release from Progenics Pharmaceuticals, Inc. discussing research presented at the 27th Annual European Association of Nuclear Medicine (EANM) Congress, Gothenburg] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
XTANDI™ (Enzalutamide) Capsules Receive Positive CHMP Opinion for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve
Astellas Pharma Europe Ltd. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending a variation to amend the marketing authorization for enzalutamide. [Astellas Pharma Europe Ltd. (Business Wire)] Press Release

Innocrin Pharmaceuticals Created as a Spin-out of the Prostate Cancer Program from Viamet Pharmaceuticals
Innocrin Pharmaceuticals, Inc., a privately held pharmaceutical company that focuses on the discovery and development of small molecule CYP17 lyase inhibitors, announced its formation as a spin-out of Viamet Pharmaceuticals, Inc. Selective lyase inhibition is an innovative approach to blocking CYP17, a validated enzyme target for the treatment of castration-resistant prostate cancer. [Innocrin Pharmaceuticals, Inc.]
Press Release

‘UK First’ Equipment to Benefit University’s Cancer Research
Nottingham Trent University’s John van Geest Cancer Research Centre has purchased a next generation mass spectrometer to support its work in improving the early diagnosis and treatment of breast and prostate cancers. [Nottingham Trent University] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 20th Association for Molecular Pathology (AMP) Annual Meeting
November 12-15, 2014
National Harbor, United States

NEW 1st Advances in Prostate Cancer Conference (APCC) & 2nd Asia Pacific Gastroenterology Cancer Summit (APGCS) 2014
November 15-16, 2014
Suntec City, Singapore

NEW 2014 World Cancer Congress
December 3-6, 2014
Melbourne, Australia

Visit our events page to see a complete list of events in the prostate cell community.
NEW Senior Research Associate – Nanomedicine (University of East Anglia)

NEW Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Physician Scientist – Prostate Cancer Genomics (University of Chicago)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Postdoctoral Position – Bioinformatics for Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Scholar – Molecular Mechanisms Underlying Tumor Cell Invasion and Metastasis (Case Western Reserve University)

Research Assistant – Clinical Prostate Cancer Research Group (Garvan Institute of Medical Research)

Postdoctoral Fellows and Graduate Student Positions (Vancouver Prostate Centre)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us